Lophos Regulatory Update
Lophos Holdings Inc. Details Strategic Outlook and Controlled Substances Licence Progress
Lophos Holdings Inc. (CSE: MESC), a Canadian bioscience company focused on regulated peyote cultivation, has announced a major leadership overhaul and a dual-track strategy to revive the business. Joshua Herman was named CEO, with Brad Cotton and Cory Harris joining the Board of Directors, according to GlobeNewswire.
The update comes as the company works to lift a Failure-to-File Cease Trade Order (CTO) issued by the Ontario Securities Commission in May 2024. Trading in Lophos shares has been frozen since the company missed its deadline to file 2023 audited financial statements, Financial Post reported.
New CEO and Board Take Charge Amid Restructuring
Joshua Herman steps in as Chief Executive Officer and joins the Board immediately. Brad Cotton and Cory Harris were also appointed as new Board members as part of the restructuring, according to Edmonton Sun. The new team is tasked with resolving the company's regulatory and financial filing issues.
The governance shake-up signals a clear break from prior leadership. Market Screener noted the company is traded on the CSE under the ticker "MESC" and is positioning itself as a bioscience pioneer in regulated plant-based and controlled substance markets. The new Board's first priority is getting the 2023 audit done to lift the trading halt.
Cease Trade Order Freezes Stock While Audit Drags On
The Ontario Securities Commission issued the CTO on May 6, 2024, after Lophos missed the filing deadline for its 2023 annual audited financials. A CTO is a legal order that stops all trading in a company's shares. Lophos shares were trading at roughly $0.05 CAD — giving the company a market cap of around $2.5M to $3M CAD — before the halt began.
Management confirmed it is working with auditors to finalize the filings and get the order revoked, Financial Post reported. Until the audit is complete and filed on SEDAR+, the shares remain frozen and investors cannot buy or sell. The company is now more than 40 days past its filing deadline.
Health Canada Licence Holds Key to Peyote Research Plans
Lophos applied to Health Canada for a Controlled Substances Dealer's Licence (CSDL) in January 2024. The licence would allow the company to extract mescaline — the active compound in peyote — and conduct clinical research. Without it, the company can grow the peyote cactus at its 10,000 sq. ft. Napanee, Ontario facility, but cannot process it for scientific use.
Peyote is one of the slowest-growing cacti on earth, taking 10 to 15 years to mature in the wild. Lophos claims its indoor cultivation methods cut that time to 3 to 5 years. GlobeNewswire noted the company sees itself as a potential first authorized large-scale supplier of peyote for Canadian research, filling a gap created by over-harvesting of wild plants in Texas and Mexico.
Lophos Essentials Brand Targets Near-Term Revenue While Waiting
While the CSDL application and audit resolution play out, Lophos is pushing a consumer wellness brand called "Lophos Essentials." The line focuses on non-controlled botanical skincare and wellness products. The goal is to generate cash flow now, without needing the Health Canada licence that unlocks the pharmaceutical side of the business.
The strategy mirrors moves made by early cannabis companies like Canopy Growth, which launched hemp-based products while waiting for complex licences. Chatham Daily News noted the company's three stated near-term milestones: complete the 2023 audit to lift the CTO, secure the CSDL after a Health Canada site inspection in Napanee, and roll out the Lophos Essentials line to retail distributors.
Sentiment
NeutralPublishers
9
Articles
9
Reach
9
